Current and Emerging Drug Delivery Needs in Oncology

Drug Delivery Needs in Oncology Due to the increasing number of parenteral biologic therapies that are administered intravenously, the already high pressure on infusion capacity and healthcare resources is expected further increase. A change from intravenous to subcutaneous dosing has been shown to reduce dosing complexity and overall drug administration related costs. There is keen interest in technologies that facilitate subcutaneous administration and potentially enable drug administration in the home setting.  Led by: Beate Bittner, PhD  Portfolio Strategy Director, Roche  Panelists: Panel: H Janice Adkins, MBA Associate Director Marketing, BD Medical The exp Pharmaceutical Systems, North America EMEA Ulrich Bruggemann Head Academics and Innovation, Global Medical Devices of the Development, Sanofi US Shawn Davis, PhD Director, Technology Strategy and Innovation, Amgen Declan Reilly Section Head, Device Engineering, Device Development PTDE-D, Roche Andrew J Yee, MD Medical Oncologist, Massachusetts General Hospital Cancer Center  This presentation took place at the 7th Annual Partnership Opportunities in Drug Delivery (PODD) 2017.